ALNY

Alnylam Pharmaceuticals Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 9/10
  • Momentum↓ 3/10
Alnylam Pharmaceuticals sales and earnings growth
ALNY Growth
Great
  • Revenue Y/Y↑ 65.19%
  • EPS Y/Y↑ 209.63%
  • FCF Y/Y↑ 1192.73%
Alnylam Pharmaceuticals gross and profit margin trends
ALNY Profitability
Great
  • Gross margin ↑ 81.60%
  • EPS margin↓ 8.40%
  • ROIC↓ 11.30%
Alnylam Pharmaceuticals net debt vs free cash flow
ALNY Risk
Poor
  • Debt / Equity↑ 3.8
  • Debt / FCF↓ 2.8
  • Interest coverage↓ 2.3

Alnylam Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

More Biotechnology stocks ↗